<DOC>
	<DOC>NCT00192244</DOC>
	<brief_summary>- The purpose of this study is to determine the efficacy of CAIV-T in a diverse Asian population aged from 6 months to less than 36 months, in tropical and temperate climates, against culture-confirmed influenza illness. In addition, the trial provides the opportunity to investigate the efficacy of CAIV-T over multiple influenza seasons, and to investigate the effect of CAIV-T on acute otitis media.</brief_summary>
	<brief_title>Trial to Determine the Safety and Efficacy of Influenza Virus Vaccine, Trivalent, Types A &amp; B, Live, Cold-Adapted (CAIV-T) in Healthy Children</brief_title>
	<detailed_description />
	<criteria>who are greater than or equal to 6 months and less than 36 months of age at the time of enrollment, and in good health as determined by medical history, physical examination, and clinical judgment; whose parent or legal guardian has provided written informed consent after the nature of the study has been explained; who, along with their parent or legal guardian, will be available for the duration of the study (24 months); whose parent/legal guardian can be reached by study staff for the postimmunization contacts [via telephone, clinic or home visits]. whose parents or caregiver are perceived to be unreliable or difficult to contact for evaluation or study visits during the study period; with any serious chronic disease (e.g., with signs of cardiac or renal failure or severe malnutrition), including progressive neurological disease; with Down's syndrome or other known cytogenetic disorders; with a known or suspected disease of the immune system or those receiving immunosuppressive therapy, including systemic corticosteroids; who received any blood products, including immunoglobulin, in the period from six months prior to vaccination through to the conclusion of the study; for whom there is intent to administer any other investigational vaccine or agent from one month prior to enrollment through to the conclusion of the study; with an immunosuppressed or compromised individual living in the same household; who, at any time prior to entry into this study, received a dose of any influenza vaccine (commercial or investigational); who were administered any live virus vaccine within one month prior to study vaccination or expected receipt of another live virus within one month of vaccination in this study; with a documented history of hypersensitivity to egg or egg protein, or any other component of the study vaccines or placebo; with a respiratory illness with wheezing within two weeks prior to enrollment; who received aspirin (acetylsalicylic acid) or aspirincontaining products in the two weeks prior to enrollment or for which use is anticipated during the study; with any medical conditions that in the opinion of the Investigator might interfere with interpretation of the study results; Note: A pregnant household member or day care provider is not considered a contraindication to enrollment.</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>35 Months</maximum_age>
	<verification_date>October 2006</verification_date>
</DOC>